<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03894215</url>
  </required_header>
  <id_info>
    <org_study_id>C-750-01/GOG-3028</org_study_id>
    <nct_id>NCT03894215</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer</brief_title>
  <official_title>A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti-CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Agenus Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Agenus Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, blinded, non-comparative, two-arm Phase 2 clinical trial to assess the
      efficacy and safety of AGEN2034 administered with placebo (Treatment Arm 1 - monotherapy) or
      with AGEN1884 (Treatment Arm 2 - combination therapy) for treatment of patients with advanced
      cervical cancer who relapsed or progressed after receiving first-line platinum-based
      chemotherapy. The study is not intended to compare the efficacy of the 2 experimental arms.
      Rather, the efficacy of each arm will be evaluated against its relevant historical controls
      as appropriate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, blinded, non-comparative, two-arm Phase 2 clinical trial to assess the
      efficacy and safety of AGEN2034 administered with placebo (Treatment Arm 1 - monotherapy) or
      with AGEN1884 (Treatment Arm 2 - combination therapy) for treatment of patients with advanced
      cervical cancer who relapsed or progressed after receiving first-line platinum-based
      chemotherapy. The study is not intended to compare the efficacy of the 2 experimental arms.
      Rather, the efficacy of each arm will be evaluated against its relevant historical controls
      as appropriate Patients will receive AGEN2034 with placebo as a monotherapy or with AGEN1884
      as combination therapy for a maximum of 24 months or until confirmed progression,
      unacceptable toxicity, or any criterion for stopping the study drug or withdrawal from the
      trial occurs. Placebo administration in Treatment Arm 1 (AGEN 2034 monotherapy) of the study
      is intended to preserve the integrity of the investigators' interpretation of the efficacy
      and safety data by eliminating biases in disease assessment monitoring, declaration of
      disease progression, and assessment of toxicities. Therefore, it is understood that
      investigators, patients, and research personnel will not know whether patients have received
      AGEN2034/placebo (Treatment Arm 1) or AGEN2034/AGEN1884 (Treatment Arm 2).

      An Independent Data Monitoring Committee (IDMC) will evaluate safety and efficacy. An IRRC
      will be established to adjudicate tumor response..
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>48 months</time_frame>
    <description>To assess the Objective Response Rate (ORR) to the treatment of AGEN2034 (anti-PD-1) administered with placebo (Treatment Arm 1 - monotherapy), or with AGEN1884 (anti-CTLA4) (Treatment Arm 2 - combination therapy), defined as the binomial proportion of intent to treat (ITT) patients with best overall response (BOR) of complete response (CR) or partial response (PR), in women with recurrent/persistent/metastatic cervical cancer who have progressed following first-line therapy. BOR will be determined by the Independent Radiology Review Committee (IRRC), according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency, severity and duration of treatment-emergent AEs</measure>
    <time_frame>48 months</time_frame>
    <description>To confirm the safety and tolerability of AGEN2034 administered with placebo (Treatment Arm 1 - monotherapy) or with AGEN1884 (Treatment Arm 2 - combination therapy) in patients with recurrent, progressive second-line cervical cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR per RECIST 1.1</measure>
    <time_frame>48 months</time_frame>
    <description>To assess duration of response (DOR), stable disease (SD), duration of stable disease and disease control rate (DCR), overall survival (OS), and progression-free survival (PFS) per RECIST 1.1 for AGEN2034 administered with placebo (Treatment Arm 1 - monotherapy) or with AGEN1884 (Treatment Arm 2 - combination therapy).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Confirmed Progression</measure>
    <time_frame>48 months</time_frame>
    <description>To estimate the time to confirmed progression by the investigator per iRECIST for AGEN2034 administered with placebo (Treatment Arm 1 - monotherapy) or with AGEN1884 (Treatment Arm 2 - combination therapy).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of AGEN2034</measure>
    <time_frame>48 months</time_frame>
    <description>To evaluate the immunogenicity of AGEN2034 administered with placebo (Treatment Arm 1 - monotherapy) or with AGEN1884 (Treatment Arm 2 - combination therapy) and to correlate it to exposure and biological activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed drug concentration at steady state (Cmax-ss)</measure>
    <time_frame>48 months</time_frame>
    <description>To characterize AGEN2034 and AGEN1884 pharmacokinetics (PK).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum observed drug concentration at steady-state (Cmin-ss)</measure>
    <time_frame>48 months</time_frame>
    <description>To characterize AGEN2034 and AGEN1884 pharmacokinetics (PK).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve within time span t1 to t2 at steady-state (AUC(τ1-τ2)-ss)</measure>
    <time_frame>48 months</time_frame>
    <description>To characterize AGEN2034 and AGEN1884 pharmacokinetics (PK).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the drug concentration-time curve from time zero to time t (AUC(0-t))</measure>
    <time_frame>48 months</time_frame>
    <description>To characterize AGEN2034 and AGEN1884 pharmacokinetics (PK).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the drug concentration-time curve from time zero to infinity (AUC(0-∞))</measure>
    <time_frame>48 months</time_frame>
    <description>To characterize AGEN2034 and AGEN1884 pharmacokinetics (PK).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum drug concentration (tmax)</measure>
    <time_frame>48 months</time_frame>
    <description>To characterize AGEN2034 and AGEN1884 pharmacokinetics (PK).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal disposition rate constant (λz)</measure>
    <time_frame>48 months</time_frame>
    <description>To characterize AGEN2034 and AGEN1884 pharmacokinetics (PK).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (t1/2)</measure>
    <time_frame>48 months</time_frame>
    <description>To characterize AGEN2034 and AGEN1884 pharmacokinetics (PK).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic clearance (CL)</measure>
    <time_frame>48 months</time_frame>
    <description>To characterize AGEN2034 and AGEN1884 pharmacokinetics (PK).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vd)</measure>
    <time_frame>48 months</time_frame>
    <description>To characterize AGEN2034 and AGEN1884 pharmacokinetics (PK).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Assessment per FACT-Cx</measure>
    <time_frame>35 months</time_frame>
    <description>To assess quality of life in the treated population using the Functional Assessment of Cancer Therapy - Cervical Cancer Trial Outcome Index (FACT-Cx)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Assessment per BPI</measure>
    <time_frame>35 months</time_frame>
    <description>To assess quality of life in the treated population using Brief Pain Inventory (BPI)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>AGEN2034 + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AGEN2034 administered with placebo monotherapy: approximately 100 patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGEN2034 + AGEN1884</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AGEN2034 administered in combination with AGEN1884 (combination therapy): approximately 100 patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGEN2034</intervention_name>
    <description>PD-1 antibody</description>
    <arm_group_label>AGEN2034 + AGEN1884</arm_group_label>
    <arm_group_label>AGEN2034 + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGEN1884</intervention_name>
    <description>CTLA-4 antibody</description>
    <arm_group_label>AGEN2034 + AGEN1884</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Voluntarily agree to participate by giving written informed consent. (Participation in
             pharmacogenomics testing is optional)

          2. Be ≥18 years of age

          3. Diagnosis:

               1. Have (1) a histologically or cytologically confirmed diagnosis of squamous-cell
                  carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix, and (2)
                  metastatic, locally advanced, and/or unresectable disease at the time of
                  enrollment. Histologic confirmation of the original primary tumor is required via
                  pathology report.

                  Note: The following cervical tumors are not eligible: minimal deviation/adenoma
                  malignum, gastric type adenocarcinoma, clear cell carcinoma, and mesonephric
                  carcinoma.

               2. Has cervical cancer and has relapsed after a platinum-based treatment (first
                  line) regimen for advanced (recurrent, unresectable, or metastatic) disease;

             Note: Patient receiving chemotherapy concurrently with primary radiation (e.g., weekly
             cisplatin) or patient receiving adjuvant chemotherapy following completion of
             radiation therapy (e.g., paclitaxel and carboplatin for ≤ 4 cycles) and progressed
             within 6 months after treatment completion will be eligible as this systemic therapy
             will be considered as first-line treatment.

          4. Measurable Disease

             a) Have measurable disease on imaging based on RECIST version 1.1 by investigator
             assessments.

             Note: Patients must have at least one &quot;target lesion&quot; to be used to assess response,
             as defined by RECIST version 1.1. Tumors within a previously irradiated field will be
             designated as &quot;non-target&quot; lesions unless progression is documented, or a biopsy is
             obtained to confirm persistence at least 90 days following completion of radiation
             therapy.

          5. Have a life expectancy of at least 3 months and an Eastern Cooperative Oncology Group
             (ECOG) performance status of 0 or 1.

          6. Have adequate organ function as indicated by the following laboratory values:

               1. Adequate hematological function defined by absolute neutrophil count (ANC) &gt; 1.5
                  x 10^9/L, platelet count &gt; 100 x 10^9/L, and hemoglobin &gt;8 g/dL (without
                  transfusions within 1 week of first dose).

               2. Adequate hepatic function based by a total bilirubin level ≤ 1.5 the
                  institutional upper limit of normal (IULN), aspartate aminotransferase (AST)
                  level ≤ 2.5 x IULN, alanine aminotransferase (ALT) level ≤ 2.5 x IULN, and
                  alkaline phosphatase ≤ 2.5 IULN and albumin ≥3.0 mg/dL.

               3. Adequate renal function defined as calculated creatinine clearance &gt;50 mL/min
                  (creatinine clearance should be calculated using the Cockcroft-Gault Method).

               4. Adequate coagulation defined by international normalized ratio (INR) or
                  prothrombin time ≤ 1.5 x IULN (unless the patient is receiving anticoagulant
                  therapy); and activated partial thromboplastin time (aPTT) ≤ 1.5 x IULN (unless
                  the patient is receiving anticoagulant therapy)

          7. Have no history of prior malignancy, with the exception of basal cell carcinoma of the
             skin, superficial bladder cancer, squamous-cell carcinoma of the skin, and has
             undergone potentially curative therapy with no evidence of that disease recurrence for
             5 years since initiation of that therapy.

          8. Patients must provide a sufficient and adequate formalin-fixed paraffin embedded
             (FFPE) tumor tissue sample preferably from the most recent biopsy of a tumor lesion,
             collected either at the time of or after the diagnosis of advanced or metastatic
             disease has been made AND from a site not previously irradiated. If no tumor tissue is
             available, a fresh biopsy will be required

             Note: Tissue from needle or excisional biopsy or from resection is required.

          9. Patients must have a negative serum pregnancy test at screening (within 72 hours of
             first dose of study medication) if of childbearing potential or be of non-child
             bearing potential. Non-childbearing potential is defined as (by other than medical
             reasons):

               1. ≥45 years of age and has not had menses for greater than 1 year,

               2. Amenorrheic ≥ 2 years without a hysterectomy and oophorectomy and a
                  follicle-stimulating hormone (FSH) value in the postmenopausal range upon
                  pretrial (screening) evaluation,

               3. History of hysterectomy, oophorectomy or tubal ligation.

               4. Definitive pelvic radiation for the treatment of cervical cancer.

         10. If of childbearing potential, female patients must be willing to use 2 adequate
             barrier methods throughout the study, starting with the screening visit through 120
             days after the last dose of study treatment.

             Note: Abstinence is acceptable if this is the established and preferred contraception
             for the patient.

         11. Is willing and able to comply with the requirements of the protocol.

        Exclusion Criteria:

        The patient must be excluded from participating in the trial if the patient:

          1. Is currently participating and receiving study therapy or has participated in a study
             of an investigational agent and received study therapy or used an investigation device
             within 4 weeks of the first dose of treatment.

          2. Has an inadequate washout period prior to first dose of study drug defined as:

               1. Received systemic cytotoxic chemotherapy or biological therapy within 3 weeks
                  before first dose,

               2. Received radiation therapy within 3 weeks before first dose, or

               3. Had major surgery within 4 weeks before first dose.

          3. Has received prior therapy with:

               1. Any antibody/drug targeting T-cell co-regulatory proteins (immune checkpoints)
                  such as anti-PD-1, anti-PD-L1, or anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4)
                  antibodies

               2. More than 1 systemic treatment regimen for the advanced (recurrent, unresectable,
                  or metastatic) cervical cancer for which the patient is considered for the study.

          4. Has persisting toxicity related to prior therapy of National Cancer Institute Common
             Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE) Grade &gt;1 severity.

             Note: Sensory neuropathy or alopecia of Grade ≤2 is acceptable.

          5. Is expected to require any other form of systemic or localized antineoplastic therapy
             while on trial (including maintenance therapy with another agent, radiation therapy,
             and/or surgical resection).

          6. Has known severe hypersensitivity reactions to fully human monoclonal antibodies
             (NCI-CTCAE Grade ≥3), any history of anaphylaxis, or uncontrolled asthma.(i.e., ≥3
             features of partly controlled asthma).

          7. Has received systemic corticosteroid therapy ≤ 7 days prior to the first dose of trial
             treatment or receiving any other form of systemic immunosuppressive medication
             (corticosteroid use on study for management of immune-related adverse events (AE),
             and/or a premedication for IV contrast allergies/reactions is allowed). Patients who
             are receiving daily corticosteroid replacement therapy are an exception to this rule.
             Daily prednisone at doses of up to 5 mg or equivalent hydrocortisone dose are examples
             of permitted replacement therapy.

          8. Has a central nervous system (CNS) tumor, metastasis(es), and/or carcinomatous
             meningitis identified either on the baseline brain imaging obtained during the
             screening period OR identified prior to consent.

             Note: Patients with history of brain metastases that have been treated may participate
             provided they show evidence of stable supra-tentorial lesions at screening (based on 2
             sets of brain images, performed ≥ 4 weeks apart, and obtained after the brain
             metastases treatment). In addition, any neurologic symptoms that developed either as a
             result of the brain metastases or their treatment must have resolved or be minimal and
             be expected as sequelae from treated lesions. For individuals who received steroids as
             part of brain metastases treatment, steroids must be discontinued ≥ 7 days prior to
             first dose of study drug.

          9. Has active or history of autoimmune disease that has required immunosuppressive
             systemic treatment within 2 years of the start of trial treatment (i.e. with use of
             disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement
             therapy (i.e., thyroxine, insulin, or physiologic corticosteroid replacement therapy
             for adrenal or pituitary insufficiency, etc.) is not considered a form of
             immunosuppressive systemic treatment.

             Note: Patients with diabetes type 1, vitiligo, psoriasis, hypo-, or hyperthyroid
             disease not requiring immunosuppressive treatment are eligible.

         10. Has had an allogeneic tissue/solid organ transplant.

         11. Has or had interstitial lung disease (ILD) OR has had a history of pneumonitis that
             has required oral or IV corticosteroids.

         12. Has an active infection requiring intravenous (IV) systemic therapy.

         13. Has known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).

         14. Has known active Hepatitis B (HBV), Hepatitis C (HCV), or tuberculosis. Active
             Hepatitis B is defined as a known positive HBsAg result. Active Hepatitis C is defined
             by a known positive Hep C Ab result and known quantitative HCV ribonucleic acid (RNA)
             results greater than the lower limits of detection of the assay.

         15. Has clinically significant (i.e., active) cardiovascular disease: cerebral vascular
             accident/stroke or myocardial infarction within 6 months of enrollment, unstable
             angina, congestive heart failure (New York Heart Association class ≥II), or serious
             uncontrolled cardiac arrhythmia requiring medication or intervention.

         16. Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial, interfere with the patient's
             participation for the full duration of the trial, or is not in the best interest of
             the patient to participate, in the opinion of the treating investigator.

         17. Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial.

         18. Is, at the time of signing informed consent, a regular user (including &quot;recreational
             use&quot;) of any illicit drugs or had a recent history (within the last year) of substance
             abuse (including alcohol). Medicinal marijuana use is not considered &quot;illicit&quot; and is
             allowed to be utilized prior to and during enrollment.

         19. Is legally incapacitated or has limited legal capacity.

         20. Is pregnant or breastfeeding or expecting to conceive within the projected duration of
             the trial, starting with the screening visit through 120 days after the last dose of
             AGEN2034 and/or AGEN1884.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Agenus Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Agenus, Inc. Clinical Trial Information</last_name>
    <phone>781-674-4265</phone>
    <email>clinicaltrialinfo@agenusbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham School of Medicine</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233-1802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rebecca Arend, MD</last_name>
      <phone>205-934-4986</phone>
      <email>rarend@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Charles Leath, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Alabama Mitchell Cancer Institute</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joanie Broemmelsiek</last_name>
      <phone>251-445-9866</phone>
      <email>jbroemmelsiek@health.southalabama.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Fillingim</last_name>
      <phone>(251) 460-6993</phone>
      <email>sefillingim@health.southalabama.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Rodney Rocconi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology - Biltmore Cancer Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trevor Smith</last_name>
      <phone>602-380-6210</phone>
      <email>trevor.smith@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Ana Flores</last_name>
      <phone>(480) 256-1664</phone>
      <email>ana.flores@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Bradley Monk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology - Tucson - Wilmot Road Location</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julie Klinker</last_name>
      <phone>520-269-3821</phone>
      <email>julie.klinker@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Buscema, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA- Women's Health Clinical Research Unit (WHCRU)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sonali Namiranian</last_name>
      <phone>310-794-9095</phone>
      <email>snamiranian@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Joshua Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gynecologic Oncology Associates</name>
      <address>
        <city>Newport</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Atessa Kiani</last_name>
      <phone>949-764-5543</phone>
      <email>atessa.kiani@hoag.org</email>
    </contact>
    <investigator>
      <last_name>Alberto Mendivil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Irvine Health</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Dich</last_name>
      <phone>714-509-2430</phone>
      <email>mdich@uci.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nidhisha Patel</last_name>
      <phone>(714) 509-2430</phone>
      <email>nidhishp@uci.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Krishnansu Tewari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katherine Bigay</last_name>
      <phone>415-514-6725</phone>
      <email>katherine.bigay@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Emilia Calderónn</last_name>
      <phone>(415) 885-7206</phone>
      <email>emilia.calderon@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Stefanie Ueda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist MD Anderson Cancer Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carol Fairchild</last_name>
      <phone>904-202-7708</phone>
      <email>carol.fairchild@bmcjax.com</email>
    </contact>
    <investigator>
      <last_name>Paul Nowicki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yazmin Rodriguez</last_name>
      <phone>813-745-4673</phone>
      <phone_ext>3353</phone_ext>
      <email>yazmin.rodriguez@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Hye Sook Chon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Cuvo</last_name>
      <phone>404-845-5341</phone>
      <email>Jennifer.cuvo@northside.com</email>
    </contact>
    <investigator>
      <last_name>Meaghan Tenney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augusta University - Georgia Cancer Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eleanor Reeves</last_name>
      <phone>706-721-6878</phone>
      <email>ereeves@augusta.edu</email>
    </contact>
    <contact_backup>
      <last_name>Andrea Townsend</last_name>
      <phone>(706) 721-3473</phone>
      <email>rtownsend@augusta.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sharad Ghamande, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Joseph's Hospital</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405-6015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julie Heintz</last_name>
      <phone>912-819-5748</phone>
      <email>heintzj@sjchs.org</email>
    </contact>
    <investigator>
      <last_name>Sarah Gill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Community Health Network - North Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melanie Wheeldon</last_name>
      <phone>317-355-2868</phone>
      <email>mwheeldon@ecommunity.com</email>
    </contact>
    <investigator>
      <last_name>William Lowery, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Albert B. Chandler Hospital</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jefferson Childs</last_name>
      <phone>859-323-4128</phone>
      <email>jefferson.childs@uky.edu</email>
    </contact>
    <contact_backup>
      <last_name>Molly Reese</last_name>
      <phone>(859) 323-3065</phone>
      <email>molly.reese@uky.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Frederick Ueland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah Nowak</last_name>
      <phone>504-703-3269</phone>
      <email>sarah.nowak@ochsner.org</email>
    </contact>
    <contact_backup>
      <last_name>Elsa Levenes</last_name>
      <phone>(504) 703-3269</phone>
      <email>elsa.levenes@ochsner.org</email>
    </contact_backup>
    <investigator>
      <last_name>Katrina Wade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215-5418</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kimberley MacNeill</last_name>
      <phone>617-632-2621</phone>
      <email>kimberley_macneill@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Susana Mar Campos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center at Cooper</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Shea</last_name>
      <phone>856-735-6323</phone>
      <email>shea-lisa@cooperhealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Robin Turton</last_name>
      <phone>(856) 735-6234</phone>
      <email>turton-robin@cooperhealth.edu</email>
    </contact_backup>
    <investigator>
      <last_name>David Warshal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summit Medical Group</name>
      <address>
        <city>Florham Park</city>
        <state>New Jersey</state>
        <zip>07932</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michelle Mackenzie</last_name>
      <phone>973-436-1755</phone>
      <email>mmackenzie@smgnj.com</email>
    </contact>
    <contact_backup>
      <last_name>Amy Lumpkin</last_name>
      <phone>(973) 538-5210</phone>
      <email>alumpkin@smgnj.com</email>
    </contact_backup>
    <investigator>
      <last_name>Darlene Gibbon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sheri Westgate</last_name>
      <phone>505-925-0383</phone>
      <email>swestgate@salud.unm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mollie Geske</last_name>
      <phone>(505) 925-0377</phone>
      <email>mgeske@nmcca.org</email>
    </contact_backup>
    <investigator>
      <last_name>Sarah Adams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maritza Padin</last_name>
      <phone>718-405-8434</phone>
      <email>mpadin@montefiore.org</email>
    </contact>
    <contact_backup>
      <last_name>Bijan Khaksari</last_name>
      <phone>(718) 405-8434</phone>
      <email>bkhaksari@montefiore.org</email>
    </contact_backup>
    <investigator>
      <last_name>Nicole Nevadunsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Laura and Isaac Perlmutter Cancer Center at NYU Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nancy Keith</last_name>
      <email>nancy.keith@nyulangone.org</email>
    </contact>
    <contact_backup>
      <last_name>David Mossa</last_name>
      <phone>(212) 263-4832</phone>
      <email>david.mossa@nyumc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Leslie Boyd, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FirstHealth Outpatient Cancer Center</name>
      <address>
        <city>Pinehurst</city>
        <state>North Carolina</state>
        <zip>28374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Mason</last_name>
      <phone>910-715-2213</phone>
      <email>pmason@firsthealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Julie Williams</last_name>
      <phone>(910) 715-1922</phone>
      <email>jcwilliams@firsthealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Sundborg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Runner</last_name>
      <phone>216-778-8306</phone>
      <email>krunner2@metrohealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Sara Standen</last_name>
      <phone>(216) 778-3526</phone>
      <email>sstanden@metrohealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Kimberly Resnick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jill Kent</last_name>
      <phone>614-685-9240</phone>
      <email>jill.kent@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Anyssa Armstead</last_name>
      <phone>(614) 688-8846</phone>
      <email>anyssa.armstead@osumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ritu Salani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbus NCORP</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pamela Collins</last_name>
      <phone>614-488-2637</phone>
      <email>pam@columbusccop.org</email>
    </contact>
    <contact_backup>
      <last_name>Debby Shaw</last_name>
      <phone>(614) 488-2118</phone>
      <email>debby@columbusccop.org</email>
    </contact_backup>
    <investigator>
      <last_name>Timothy Moore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104-5418</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah Brown</last_name>
      <phone>405-271-8707</phone>
      <email>Sarah-E-Brown@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Camille Gunderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oklahoma Cancer Specialists and Research Institute, LLC</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Powell</last_name>
      <phone>918-505-3201</phone>
      <email>melissa.powell@ocrsi.org</email>
    </contact>
    <contact_backup>
      <last_name>Jan Byerly</last_name>
      <phone>(281) 296-0365</phone>
      <email>jan.byerly@ocsri.org</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Gold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Institute</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Anderson, MD</last_name>
      <phone>541-988-0671</phone>
      <email>Charles.anderson@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Charles Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Valerie Premore</last_name>
      <phone>503-528-5002</phone>
      <email>valerie.premore@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Susan Papenfuse</last_name>
      <phone>(360) 449-6521</phone>
      <email>susan.papenfuse@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Erin Salinas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn Medicine - Jordan Center for Gynecologic Cancer</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-5127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>K. Schuyler Nissen</last_name>
      <phone>215-615-6768</phone>
      <email>schuyler.nissen@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Lainie Martin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WellSpan Gynecologic Oncology</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Merry Jo Keesee</last_name>
      <phone>717-741-8316</phone>
      <email>mkeesee@wellspan.org</email>
    </contact>
    <contact_backup>
      <last_name>Erica Zahos</last_name>
      <phone>(717) 741-8123</phone>
      <email>ezahos@wellspan.org</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women &amp; Infants Hospital of Rhode Island</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emma Locke</last_name>
      <phone>401-274-1122</phone>
      <phone_ext>48553</phone_ext>
      <email>elocke@wihri.org</email>
    </contact>
    <contact_backup>
      <last_name>Alvaro Beltran</last_name>
      <phone>(401) 274-1122</phone>
      <phone_ext>48553</phone_ext>
      <email>abeltran@wihri.org</email>
    </contact_backup>
    <investigator>
      <last_name>Matthew Oliver, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Surgical Specialists - Austin Central</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patricia Janeczko</last_name>
      <phone>512-912-2761</phone>
      <email>patricia.janeczko@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Monica Arellano</last_name>
      <phone>(512) 912-2765</phone>
      <email>monica.arellano@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Teneriello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Bedford</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <zip>76022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shawna Bowers</last_name>
      <phone>817-359-9098</phone>
      <email>shawnna.bowers@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Sandy Mathews</last_name>
      <phone>(817) 359-9033</phone>
      <email>sandy.mathews@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Messing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Dallas - Presbyterian Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine Barter</last_name>
      <phone>972-768-6996</phone>
      <email>catherine.barter@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Tracy Messing</last_name>
      <phone>(214) 739-4175</phone>
      <email>txopresbydalresearch@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kristi McIntyre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Miller, MD</last_name>
      <phone>214-648-3026</phone>
      <email>david.miller@UTsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>David Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Fort Worth Cancer Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tina Morris</last_name>
      <phone>817-413-1667</phone>
      <email>tina.morris@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Faith Selzer</last_name>
      <phone>(817) 413-1648</phone>
      <email>faith.selzer@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Noelle Cloven, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - San Antonio Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Debora Lind</last_name>
      <phone>210-595-5682</phone>
      <email>debora.lind@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Lori Molbe</last_name>
      <phone>(210) 424-2609</phone>
      <email>lorinda.molbe@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Antonio Santillan-Gomez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - The Woodlands</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ruth Lopez</last_name>
      <phone>281-296-0365</phone>
      <email>ruth.lopez1@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Riegel</last_name>
      <email>stephanie.riegel@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Christine Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Penny Watkins</last_name>
      <phone>903-579-9899</phone>
      <email>penny.watkins@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Castner</last_name>
      <phone>(903) 579-9800</phone>
      <email>jennifer.castner@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Donald Richards, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Allie SR, Zhang W, Fuse S, Usherwood EJ. Programmed death 1 regulates development of central memory CD8 T cells after acute viral infection. J Immunol. 2011 Jun 1;186(11):6280-6. doi: 10.4049/jimmunol.1003870. Epub 2011 Apr 27.</citation>
    <PMID>21525385</PMID>
  </results_reference>
  <results_reference>
    <citation>Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, Narwal R, Steele K, Gu Y, Karakunnel JJ, Rizvi NA. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 2016 Mar;17(3):299-308. doi: 10.1016/S1470-2045(15)00544-6. Epub 2016 Feb 6.</citation>
    <PMID>26858122</PMID>
  </results_reference>
  <results_reference>
    <citation>Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, Jäger D, Pietanza MC, Le DT, de Braud F, Morse MA, Ascierto PA, Horn L, Amin A, Pillai RN, Evans J, Chau I, Bono P, Atmaca A, Sharma P, Harbison CT, Lin CS, Christensen O, Calvo E. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016 Jul;17(7):883-895. doi: 10.1016/S1470-2045(16)30098-5. Epub 2016 Jun 4. Erratum in: Lancet Oncol. 2016 Jul;17 (7):e270. Erratum in: Lancet Oncol. 2019 Feb;20(2):e70.</citation>
    <PMID>27269741</PMID>
  </results_reference>
  <results_reference>
    <citation>Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006 Feb 9;439(7077):682-7. Epub 2005 Dec 28.</citation>
    <PMID>16382236</PMID>
  </results_reference>
  <results_reference>
    <citation>Borcoman E, Le Tourneau C. Pembrolizumab in cervical cancer: latest evidence and clinical usefulness. Ther Adv Med Oncol. 2017 Jun;9(6):431-439. doi: 10.1177/1758834017708742. Epub 2017 May 8. Review.</citation>
    <PMID>28607581</PMID>
  </results_reference>
  <results_reference>
    <citation>Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, Izzeddine H, Marabelle A, Champiat S, Berdelou A, Lanoy E, Texier M, Libenciuc C, Eggermont AM, Soria JC, Mateus C, Robert C. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016 Aug;13(8):473-86. doi: 10.1038/nrclinonc.2016.58. Epub 2016 May 4. Review.</citation>
    <PMID>27141885</PMID>
  </results_reference>
  <results_reference>
    <citation>Bristol-Myers Squibb USA, 2017a. Opdivo® (nivolumab) package insert,</citation>
  </results_reference>
  <results_reference>
    <citation>Bristol-Myers Squibb USA, 2017b. Yervoy® (ipilimumab) package insert,</citation>
  </results_reference>
  <results_reference>
    <citation>Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol. 2016 Feb;39(1):98-106. doi: 10.1097/COC.0000000000000239. Review.</citation>
    <PMID>26558876</PMID>
  </results_reference>
  <results_reference>
    <citation>Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S, Knee DA, Wilson NS, Dranoff G, Brogdon JL. Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med. 2013 Aug 26;210(9):1685-93. doi: 10.1084/jem.20130573. Epub 2013 Jul 29.</citation>
    <PMID>23897982</PMID>
  </results_reference>
  <results_reference>
    <citation>Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol. 2010 Oct;37(5):473-84. doi: 10.1053/j.seminoncol.2010.09.001. Review.</citation>
    <PMID>21074063</PMID>
  </results_reference>
  <results_reference>
    <citation>Camacho LH. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations. Cancer Med. 2015 May;4(5):661-72. doi: 10.1002/cam4.371. Epub 2015 Jan 25. Review.</citation>
    <PMID>25619164</PMID>
  </results_reference>
  <results_reference>
    <citation>Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR Jr, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA; CheckMate 026 Investigators. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med. 2017 Jun 22;376(25):2415-2426. doi: 10.1056/NEJMoa1613493.</citation>
    <PMID>28636851</PMID>
  </results_reference>
  <results_reference>
    <citation>Carlino, M.S. et al., 2017. KEYNOTE-029: Efficacy and safety of pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma. In ASCO Annual Meeting. Chicago.</citation>
  </results_reference>
  <results_reference>
    <citation>Chand D, Savistky D, Gonzalez A,, et al. [Abstract]. J Immunother Cancer. 2017;5(Suppl2):P312.</citation>
  </results_reference>
  <results_reference>
    <citation>Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol. 2004 Jul 15;173(2):945-54.</citation>
    <PMID>15240681</PMID>
  </results_reference>
  <results_reference>
    <citation>Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist. 2008 Jun;13(6):725-32. doi: 10.1634/theoncologist.2008-0012. Review.</citation>
    <PMID>18586928</PMID>
  </results_reference>
  <results_reference>
    <citation>Chung HC, Schellens JHM, Delord JP, et al. 2018. Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study. [ASCO abstract 5522]. J Clin Oncol. 36(15 suppl):5522.</citation>
  </results_reference>
  <results_reference>
    <citation>Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, Callahan M, Wolchok JD, Halaban R, Dhodapkar MV, Dhodapkar KM. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol. 2015 Feb 1;194(3):950-9. doi: 10.4049/jimmunol.1401686. Epub 2014 Dec 24.</citation>
    <PMID>25539810</PMID>
  </results_reference>
  <results_reference>
    <citation>Disis ML. Immune regulation of cancer. J Clin Oncol. 2010 Oct 10;28(29):4531-8. doi: 10.1200/JCO.2009.27.2146. Epub 2010 Jun 1.</citation>
    <PMID>20516428</PMID>
  </results_reference>
  <results_reference>
    <citation>Drescher, C., Moore, M.N., Liu, J., O'Malley, D.M., Wang, E.W., Wang, J.S-Z., Subbish, V., et al. Phase 1/2, Open-Label, Multiple Ascending Dose Trial of AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Advanced Solid Malignancies: Results of Dose Escalation in Advanced Cancer and Expansion Cohorts in Subjects With Relapsed/Refractory Cervical Cancer. Poster presented at European Society for Medical Oncology. Poster presented at ESMO 2018 Congress; 19 - 23 Oct 2018; Munich, Germany; Poster 1158P. Ann Oncol 2018 Oct; 29(Suppl 8).</citation>
  </results_reference>
  <results_reference>
    <citation>Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Bastholt L, Mortier L, Thomas L, Tahir S, Hauschild A, Hassel JC, Hodi FS, Taitt C, de Pril V, de Schaetzen G, Suciu S, Testori A. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med. 2016 Nov 10;375(19):1845-1855. Epub 2016 Oct 7. Erratum in: N Engl J Med. 2018 Nov 29;379(22):2185.</citation>
    <PMID>27717298</PMID>
  </results_reference>
  <results_reference>
    <citation>Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.</citation>
    <PMID>19097774</PMID>
  </results_reference>
  <results_reference>
    <citation>Food and Drug Administration. 2018. FDA approves pembrolizumab for advanced cervical cancer with disease progression during or after chemotherapy. https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm610572.htm. Accessed 14 January 2019.</citation>
  </results_reference>
  <results_reference>
    <citation>Frenel, J.-S. et al., 2017. Pembrolizumab in patients with advanced cervical squamous cell cancer: Preliminary results from the phase Ib KEYNOTE-028 study. Journal of Clinical Oncology, 34(suppl; abstr 5515).</citation>
  </results_reference>
  <results_reference>
    <citation>Goldman, J.W. et al., 2017. Nivolumab (N) plus ipilimumab (I) as first-line (1L) treatment for advanced (adv) NSCLC: 2-yr OS and long-term outcomes from CheckMate 012. In ASCO Annual Meeting. Chicago.</citation>
  </results_reference>
  <results_reference>
    <citation>Gombos RB, Gonzalez A, Manrique M, Chand D, Savitsky D, Morin B, Breous-Nystrom E, Dupont C, Ward RA, Mundt C, Duckless B, Tang H, Findeis MA, Schuster A, Waight JD, Underwood D, Clarke C, Ritter G, Merghoub T, Schaer D, Wolchok JD, van Dijk M, Buell JS, Cuillerot JM, Stein R, Drouin EE, Wilson NS. Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody. PLoS One. 2018 Apr 4;13(4):e0191926. doi: 10.1371/journal.pone.0191926. eCollection 2018.</citation>
    <PMID>29617360</PMID>
  </results_reference>
  <results_reference>
    <citation>Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther. 2017 Nov;16(11):2598-2608. doi: 10.1158/1535-7163.MCT-17-0386. Epub 2017 Aug 23.</citation>
    <PMID>28835386</PMID>
  </results_reference>
  <results_reference>
    <citation>Hammers HJ, Plimack ER, Infante JR, Rini BI, McDermott DF, Lewis LD, Voss MH, Sharma P, Pal SK, Razak ARA, Kollmannsberger C, Heng DYC, Spratlin J, McHenry MB, Amin A. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. J Clin Oncol. 2017 Dec 1;35(34):3851-3858. doi: 10.1200/JCO.2016.72.1985. Epub 2017 Jul 5.</citation>
    <PMID>28678668</PMID>
  </results_reference>
  <results_reference>
    <citation>Hellmann, M.D. et al., 2016. CheckMate 012: safety and efficacy of first-line nivolumab and ipilimumab in advanced NSCLC. In ASCO Annual Meeting. Chicago: Proc Am Soc Clin Oncol.</citation>
  </results_reference>
  <results_reference>
    <citation>Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, Ready NE, Gerber DE, Chow LQ, Juergens RA, Shepherd FA, Laurie SA, Geese WJ, Agrawal S, Young TC, Li X, Antonia SJ. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017 Jan;18(1):31-41. doi: 10.1016/S1470-2045(16)30624-6. Epub 2016 Dec 5.</citation>
    <PMID>27932067</PMID>
  </results_reference>
  <results_reference>
    <citation>Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atmaca A, Rizvi NA, Hirsch FR, Selvaggi G, Szustakowski JD, Sasson A, Golhar R, Vitazka P, Chang H, Geese WJ, Antonia SJ. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell. 2018 May 14;33(5):853-861.e4. doi: 10.1016/j.ccell.2018.04.001. Epub 2018 May 3. Erratum in: Cancer Cell. 2019 Feb 11;35(2):329.</citation>
    <PMID>29731394</PMID>
  </results_reference>
  <results_reference>
    <citation>Hellmann MD, Nathanson T, Rizvi H, Creelan BC, Sanchez-Vega F, Ahuja A, Ni A, Novik JB, Mangarin LMB, Abu-Akeel M, Liu C, Sauter JL, Rekhtman N, Chang E, Callahan MK, Chaft JE, Voss MH, Tenet M, Li XM, Covello K, Renninger A, Vitazka P, Geese WJ, Borghaei H, Rudin CM, Antonia SJ, Swanton C, Hammerbacher J, Merghoub T, McGranahan N, Snyder A, Wolchok JD. Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell. 2018 May 14;33(5):843-852.e4. doi: 10.1016/j.ccell.2018.03.018. Epub 2018 Apr 12.</citation>
    <PMID>29657128</PMID>
  </results_reference>
  <results_reference>
    <citation>Hollebecque, A. et al., 2017. An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers. Journal of Clinical Oncology, 35(suppl;abstr 5504).</citation>
  </results_reference>
  <results_reference>
    <citation>Huang G, Sun X, Liu D, Zhang Y, Zhang B, Xiao G, Li X, Gao X, Hu C, Wang M, Ren H, Qin S. The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis. Oncotarget. 2017 Dec 15;9(3):4239-4248. doi: 10.18632/oncotarget.23279. eCollection 2018 Jan 9.</citation>
    <PMID>29423118</PMID>
  </results_reference>
  <results_reference>
    <citation>Jia M, Feng W, Kang S, Zhang Y, Shen J, He J, Jiang L, Wang W, Guo Z, Peng G, Chen G, He J, Liang W. Evaluation of the efficacy and safety of anti-PD-1 and anti-PD-L1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis. J Thorac Dis. 2015 Mar;7(3):455-61. doi: 10.3978/j.issn.2072-1439.2015.02.06.</citation>
    <PMID>25922725</PMID>
  </results_reference>
  <results_reference>
    <citation>Keytruda [package insert]. Whitehouse Station, NJ; Merck and Co, Inc; 2018.</citation>
  </results_reference>
  <results_reference>
    <citation>Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. Front Pharmacol. 2017 Feb 8;8:49. doi: 10.3389/fphar.2017.00049. eCollection 2017. Review. Erratum in: Front Pharmacol. 2017 May 31;8:311.</citation>
    <PMID>28228726</PMID>
  </results_reference>
  <results_reference>
    <citation>Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015 Sep 24;373(13):1270-1. doi: 10.1056/NEJMc1509660. Erratum in: N Engl J Med. 2018 Nov 29;379(22):2185.</citation>
    <PMID>26398076</PMID>
  </results_reference>
  <results_reference>
    <citation>Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA, Carter LL, Carreno BM, Malenkovich N, Nishimura H, Okazaki T, Honjo T, Sharpe AH, Freeman GJ. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001 Mar;2(3):261-8.</citation>
    <PMID>11224527</PMID>
  </results_reference>
  <results_reference>
    <citation>Long, G.V. et al., 2016. Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort. Journal of Clinical Oncology, 34(15_suppl), pp.9506-9506.</citation>
  </results_reference>
  <results_reference>
    <citation>Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, Rajapaksa R, Green MR, Torchia J, Brody J, Luong R, Rosenblum MD, Steinman L, Levitsky HI, Tse V, Levy R. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest. 2013 Jun;123(6):2447-63. Erratum in: J Clin Invest. 2013 Nov;123(11):4980.</citation>
    <PMID>23728179</PMID>
  </results_reference>
  <results_reference>
    <citation>Mezache L, Paniccia B, Nyinawabera A, Nuovo GJ. Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers. Mod Pathol. 2015 Dec;28(12):1594-602. doi: 10.1038/modpathol.2015.108. Epub 2015 Sep 25.</citation>
    <PMID>26403783</PMID>
  </results_reference>
  <results_reference>
    <citation>National Comprehensive Cancer Network, 2016. NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer. Version 1.2017,</citation>
  </results_reference>
  <results_reference>
    <citation>Oken, M.M. et al., 1982. Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology, 5(6), pp.649-655.Ott, P.A. et al., 2017. Combination immunotherapy: a road map. Journal for Immunotherapy of Cancer, 5(1), p.16.</citation>
  </results_reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 19, 2019</study_first_submitted>
  <study_first_submitted_qc>March 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2019</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

